La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Arrowhead Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Arrowhead Pharmaceuticals' Il CEO è Chris Anzalone, nominato in Dec2007, e ha un mandato di 16.67 anni. la retribuzione annua totale è $ 9.92M, composta da 9.1% di stipendio e 90.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.99% delle azioni della società, per un valore di $ 84.33M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.1 anni e 13.8 anni.
Informazioni chiave
Chris Anzalone
Amministratore delegato
US$9.9m
Compenso totale
| Percentuale dello stipendio del CEO | 9.1% |
| Mandato del CEO | 16.7yrs |
| Proprietà del CEO | 3.0% |
| Durata media del management | 6.1yrs |
| Durata media del Consiglio di amministrazione | 13.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12
Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
| Jun 30 2018 | n/a | n/a | -US$54m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | n/a | n/a | -US$35m |
| Sep 30 2017 | US$2m | US$616k | -US$34m |
Compensazione vs Mercato: La retribuzione totale di Chris ($USD 9.92M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Chris Anzalone (55 yo)
16.7yrs
Mandato
US$9,918,093
Compensazione
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 16.7yrs | US$9.92m | 2.99% $ 93.8m | |
| Chief Financial Officer | 14.5yrs | US$3.12m | 0.19% $ 5.9m | |
| COO, General Counsel & Secretary | 9.7yrs | US$3.31m | 0.23% $ 7.2m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.16% $ 5.2m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | Nessun dato | Nessun dato | |
| Head of Investor Relations & VP | no data | Nessun dato | Nessun dato | |
| Director of Communications | 19yrs | Nessun dato | Nessun dato | |
| Chief Medical Scientist | less than a year | US$16.34m | Nessun dato | |
| Head of Toxicology & VP | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 2.2yrs | US$2.97m | 0.013% $ 422.3k | |
| Head of Tax | 2.6yrs | Nessun dato | Nessun dato | |
| VP & Treasurer | 2.6yrs | Nessun dato | Nessun dato |
6.1yrs
Durata media
60yo
Età media
Gestione esperta: Il team dirigenziale di ARWR è esperto e expertise (durata media dell'incarico 6.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 16.7yrs | US$9.92m | 2.99% $ 93.8m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | Nessun dato | Nessun dato | |
| Chairman of the Board | 13.8yrs | US$474.60k | 0.11% $ 3.5m | |
| Independent Lead Director | 12.7yrs | US$459.60k | 0.074% $ 2.3m | |
| Independent Director | 6.6yrs | US$469.60k | 0.026% $ 829.9k | |
| Member of Hepatitis B Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 14yrs | US$459.60k | 0.037% $ 1.2m | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Hepatitis B Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Hepatitis B Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Hepatitis B Clinical Advisory Board | no data | Nessun dato | Nessun dato |
13.8yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di ARWR è composto da personale esperto e esperto (durata media dell'incarico 13.8 anni).